Please note: this site relies heavily on the use of javascript. Without a javascript-enabled browser, this site will not function correctly. Please enable javascript and reload the page, or switch to a different browser.
53  structures 7588  species 0  interactions 9465  sequences 65  architectures

Family: Arginosuc_synth (PF00764)

Summary: Arginosuccinate synthase

Pfam includes annotations and additional family information from a range of different sources. These sources can be accessed via the tabs below.

This is the Wikipedia entry entitled "Argininosuccinate synthase". More...

Argininosuccinate synthase Edit Wikipedia article

Argininosuccinate synthetase
Protein ASS1 PDB 2nz2.png
Crystallographic structure of human argininosuccinate synthetase.[1]
EC number6.3.4.5
CAS number9023-58-9
IntEnzIntEnz view
ExPASyNiceZyme view
MetaCycmetabolic pathway
PDB structuresRCSB PDB PDBe PDBsum
Gene OntologyAmiGO / QuickGO
Argininosuccinate synthetase 1
NCBI gene445
Other data
EC number6.3.4.5
LocusChr. 9 q34.1
Argininosuccinate synthetase
PDB 1j21 EBI.jpg
crystal structure of thermus thermophilus hb8 argininosuccinate synthetase in complex with atp and citrulline
Pfam clanCL0039

Argininosuccinate synthase or synthetase (ASS; EC is an enzyme that catalyzes the synthesis of argininosuccinate from citrulline and aspartate. In humans, argininosuccinate synthase is encoded by the ASS gene located on chromosome 9.

ASS is responsible for the third step of the urea cycle and one of the reactions of the citrulline-NO cycle.


The expressed ASS gene is at least 65 kb in length, including at least 12 introns.[2] In humans, ASS is expressed mostly in the cells of the liver and kidney.


In the first step of the catalyzed reaction, citrulline attacks the α-phosphate of ATP to form citrulline adenylate, a reactive intermediate. The attachment of AMP to the ureido (urea-like) group on citrulline activates the carbonyl center for subsequent nucleophilic attack. This activation facilitates the second step, in which the α-amino group of aspartate attacks the ureido group. Attack by aspartate is the rate-limiting step of the reaction. This step produces free AMP and L-argininosuccinate.[3]

Thermodynamically, adenylation of the citrulline ureido group is more favorable than the analogous phosphorylation. Additionally, attack by citrulline at the α-phosphate of ATP produces an equivalent of pyrophosphate, which can be hydrolyzed in a thermodynamically favorable reaction to provide additional energy to drive the adenylation.[4]

Reaction catalyzed by argininosuccinate synthetase. Adapted from Goto et al. 2003.[5]



Argininosuccinate synthetase is a homotetramer, with each subunit consisting of 412 residues.[6] The interfaces between subunits contain a number of salt bridges and hydrogen bonds, and the C-terminus of each subunit is involved in oligomerization by interacting with the C-termini and nucleotide-binding domains of the other subunits.[7]

Active site

X-ray crystal structures have been generated for argininosuccinate synthetase from Thermus thermophilus, E. coli, Thermotoga maritime, and Homo sapiens. In ASS from T. thermophilus, E. coli, and H. sapiens, citrulline and aspartate are tightly bound in the active site by interactions with serine and arginine residues; interactions of the substrates with other residues in the active site vary by species. In T. thermophilus, the ureido group of citrulline appears to be repositioned during nucleophilic attack to attain sufficient proximity to the α-phosphate of ATP.[5] In E. coli, it is suggested that binding of ATP causes a conformational shift that brings together the nucleotide-binding domain and the synthetase domain.[8] An argininosuccinate synthetase structure with a bound ATP in the active site has not been attained, although modeling suggests that the distance between ATP and the ureido group of citrulline is smaller in human argininosuccinate synthetase than in the E. coli variety, so it is likely that a much smaller conformational change is necessary for catalysis.[7] The ATP binding domain of argininosuccinate synthetase is similar to that of other N-type ATP pyrophosphatases.[8]

Active site of argininosuccinate synthetase shown with bound citrulline, ATP, and aspartate interacting with select active site residues. Modeled using PyMol from PDB 1J1Z.


Argininosuccinate synthetase is involved in the synthesis of creatine, polyamines, arginine, urea, and nitric oxide.[9]

Arginine synthesis

The transformation of citrulline into argininosuccinate is the rate-limiting step in arginine synthesis. The activity of argininosuccinate synthetase in arginine synthesis occurs largely in at the outer mitochondrial membrane of periportal liver cells as part of the urea cycle, with some activity occurring in cortical kidney cells.[6]{[9] Genetic defects that cause incorrect localization of argininosuccinate synthetase to the outer mitochondrial membrane cause type II citrullinemia.[9]

In fetuses and infants, arginine is also produced via argininosuccinate synthetase activity in intestinal cells, presumably to supplement the low level of arginine found in mother’s milk. Expression of argininosuccinate synthetase in the intestines ceases after two to three years of life.[9]

It is thought that regulation of argininosuccinate synthetase activity in arginine synthesis occurs primarily at the transcriptional level in response to glucocorticoids, cAMP, glucagon, and insulin.[10] It has also been demonstrated in vitro that arginine down-regulates argininosuccinate synthetase expression, while citrulline up-regulates it.[9]

Citrulline-NO cycle

The enzyme endothelial nitric oxide synthase produces nitric oxide from arginine in endothelial cells.[9] Argininosuccinate synthetase and argininosuccinate lyase recycle citrulline, a byproduct of nitric oxide production, into arginine. Since nitric oxide is an important signaling molecule, this role of ASS is important to vascular physiology. In this role, argininosuccinate synthetase activity is regulated largely by inflammatory cellular signal molecules such as cytokines.[6]

In endothelial cells, it has been shown that ASS expression is increased by laminar shear stress due to pulsative blood flow.[11] Emerging evidence suggests that ASS may also be subject to regulation by phosphorylation at the Ser-328 residue by protein kinase C-α[12] and by nitrosylation at the Cys-132 residue by nitric oxide synthase.[7]

Role in disease


Citrullinemia is an inherited autosomal recessive disease.[13] At least 50 mutations that cause type I citrullinemia have been identified in the ASS gene. Most of these mutations substitute one amino acid for another in ASS. These mutations likely affect the structure of the enzyme and its ability to bind to citrulline, aspartate, and other molecules. A few mutations lead to the production of an abnormally short enzyme that cannot effectively play its role in the urea cycle.

Defects in ASS disrupt the third step of the urea cycle, preventing the liver from processing excess nitrogen into urea. As a result, nitrogen (in the form of ammonia) and other byproducts of the urea cycle (such as citrulline) build up in the bloodstream. Ammonia is toxic, particularly to the nervous system. An accumulation of ammonia during the first few days of life leads to poor feeding, vomiting, seizures, and the other signs and symptoms of type I citrullinemia.

Treatment for this defect includes a low-protein diet and dietary supplementation with arginine and phenylacetate. Arginine allows the urea cycle to complete itself, creating the substrates needed to originally fix ammonia. This will lower blood pH. Additionally, phenylacetate reacts with backed-up glutamine, resulting on phenylacetoglutamine, which can be excreted renally.[14]


A lack of argininosuccinate synthetase expression has been observed in several types of cancer cells, including pancreatic cancer, liver cancer,[15] and melanoma.[16] For example, defects in ASS have been seen in 87% of pancreatic cancers. Cancer cells are therefore unable to synthesize enough arginine for cellular processes and so must rely on dietary arginine. Depletion of plasma arginine using arginine deiminase has been shown to lead to regression of tumours in mice.[17]

See also


  1. ^ PDB: 2nz2​; Karlberg T, Collins R, van den Berg S, Flores A, Hammarström M, Högbom M, Holmberg Schiavone L, Uppenberg J (March 2008). "Structure of human argininosuccinate synthetase" (PDF). Acta Crystallographica Section D. 64 (Pt 3): 279–86. doi:10.1107/S0907444907067455. PMID 18323623.
  2. ^ Freytag SO, Beaudet AL, Bock HG, O'Brien WE (October 1984). "Molecular structure of the human argininosuccinate synthetase gene: occurrence of alternative mRNA splicing". Molecular and Cellular Biology. 4 (10): 1978–84. doi:10.1128/MCB.4.10.1978. PMC 369014. PMID 6095035.
  3. ^ Ghose C, Raushel FM (October 1985). "Determination of the mechanism of the argininosuccinate synthetase reaction by static and dynamic quench experiments". Biochemistry. 24 (21): 5894–8. doi:10.1021/bi00342a031. PMID 3878725.
  4. ^ Kumar S, Lennane J, Ratner S (October 1985). "Argininosuccinate synthetase: essential role of cysteine and arginine residues in relation to structure and mechanism of ATP activation". Proceedings of the National Academy of Sciences of the United States of America. 82 (20): 6745–9. doi:10.1073/pnas.82.20.6745. PMC 390763. PMID 3863125.
  5. ^ a b Goto M, Omi R, Miyahara I, Sugahara M, Hirotsu K (June 2003). "Structures of argininosuccinate synthetase in enzyme-ATP substrates and enzyme-AMP product forms: stereochemistry of the catalytic reaction". The Journal of Biological Chemistry. 278 (25): 22964–71. doi:10.1074/jbc.M213198200. PMID 12684518.
  6. ^ a b c Husson A, Brasse-Lagnel C, Fairand A, Renouf S, Lavoinne A (May 2003). "Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle". European Journal of Biochemistry. 270 (9): 1887–99. doi:10.1046/j.1432-1033.2003.03559.x. PMID 12709047.
  7. ^ a b c Karlberg T, Collins R, van den Berg S, Flores A, Hammarström M, Högbom M, Holmberg Schiavone L, Uppenberg J (March 2008). "Structure of human argininosuccinate synthetase" (PDF). Acta Crystallographica Section D. 64 (Pt 3): 279–86. doi:10.1107/S0907444907067455. PMID 18323623.
  8. ^ a b Lemke CT, Howell PL (December 2001). "The 1.6 A crystal structure of E. coli argininosuccinate synthetase suggests a conformational change during catalysis". Structure. 9 (12): 1153–64. doi:10.1016/S0969-2126(01)00683-9. PMID 11738042.
  9. ^ a b c d e f Haines RJ, Pendleton LC, Eichler DC (2011). "Argininosuccinate synthase: at the center of arginine metabolism". International Journal of Biochemistry and Molecular Biology. 2 (1): 8–23. PMC 3074183. PMID 21494411.
  10. ^ Morris SM (2002). "Regulation of enzymes of the urea cycle and arginine metabolism". Annual Review of Nutrition. 22: 87–105. doi:10.1146/annurev.nutr.22.110801.140547. PMID 12055339.
  11. ^ Mun GI, Boo YC (April 2012). "A regulatory role of Kruppel-like factor 4 in endothelial argininosuccinate synthetase 1 expression in response to laminar shear stress". Biochemical and Biophysical Research Communications. 420 (2): 450–5. doi:10.1016/j.bbrc.2012.03.016. PMID 22430140.
  12. ^ Haines RJ, Corbin KD, Pendleton LC, Eichler DC (July 2012). "Protein kinase Cα phosphorylates a novel argininosuccinate synthase site at serine 328 during calcium-dependent stimulation of endothelial nitric-oxide synthase in vascular endothelial cells". The Journal of Biological Chemistry. 287 (31): 26168–76. doi:10.1074/jbc.M112.378794. PMC 3406701. PMID 22696221.
  13. ^ Häberle J, Pauli S, Linnebank M, Kleijer WJ, Bakker HD, Wanders RJ, Harms E, Koch HG (April 2002). "Structure of the human argininosuccinate synthetase gene and an improved system for molecular diagnostics in patients with classical and mild citrullinemia". Human Genetics. 110 (4): 327–33. doi:10.1007/s00439-002-0686-6. PMID 11941481.
  14. ^ Devlin TM (2002). Textbook of biochemistry: with clinical correlations. New York: Wiley-Liss. p. 788. ISBN 0-471-41136-1.
  15. ^ Wu L, Li L, Meng S, Qi R, Mao Z, Lin M (February 2013). "Expression of argininosuccinate synthetase in patients with hepatocellular carcinoma". Journal of Gastroenterology and Hepatology. 28 (2): 365–8. doi:10.1111/jgh.12043. PMID 23339388.
  16. ^ Yoon JK, Frankel AE, Feun LG, Ekmekcioglu S, Kim KB (2013). "Arginine deprivation therapy for malignant melanoma". Clinical Pharmacology. 5: 11–9. doi:10.2147/CPAA.S37350. PMC 3534294. PMID 23293541.
  17. ^ Bowles TL, Kim R, Galante J, Parsons CM, Virudachalam S, Kung HJ, Bold RJ (October 2008). "Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase". International Journal of Cancer. 123 (8): 1950–5. doi:10.1002/ijc.23723. PMC 4294549. PMID 18661517.

External links

This page is based on a Wikipedia article. The text is available under the Creative Commons Attribution/Share-Alike License.

This tab holds the annotation information that is stored in the Pfam database. As we move to using Wikipedia as our main source of annotation, the contents of this tab will be gradually replaced by the Wikipedia tab.

Arginosuccinate synthase Provide feedback

This family contains a PP-loop motif [1].

Literature references

  1. Bork P, Koonin EV; , Proteins 1994;20:347-355.: A P-loop-like motif in a widespread ATP pyrophosphatase domain: implications for the evolution of sequence motifs and enzyme activity. PUBMED:7731953 EPMC:7731953

Internal database links

External database links

This tab holds annotation information from the InterPro database.

InterPro entry IPR001518

Argininosuccinate synthase ( EC ) (AS) is a urea cycle enzyme that catalyzes the penultimate step in arginine biosynthesis: the ATP-dependent ligation of citrulline to aspartate to form argininosuccinate, AMP and pyrophosphate [ PUBMED:2123815 , PUBMED:3133361 ].

In humans, a defect in the AS gene causes citrullinemia, a genetic disease characterised by severe vomiting spells and mental retardation.

AS is a homotetrameric enzyme of chains of about 400 amino-acid residues. An arginine seems to be important for the enzyme's catalytic mechanism. The sequences of AS from various prokaryotes, archaebacteria and eukaryotes show significant similarity.

Gene Ontology

The mapping between Pfam and Gene Ontology is provided by InterPro. If you use this data please cite InterPro.

Domain organisation

Below is a listing of the unique domain organisations or architectures in which this domain is found. More...

Loading domain graphics...

Pfam Clan

This family is a member of clan HUP (CL0039), which has the following description:

The HUP class contains the HIGH-signature proteins, UspA superfamily and the PP-ATPase superfamily [1]. The HIGH superfamily has the HIGH Nucleotidyl transferases and the class I tRNA synthetases both of which have the HIGH and the KMSKS motif [1],[2]. The PP-loop ATPase named after the ATP PyroPhosphatase domain, was initially identified as a conserved amino acid sequence motif in four distinct groups of enzymes that catalyse the hydrolysis of the alpha-beta phosphate bond of ATP, namely GMP synthetases, argininosuccinate synthetases, asparagine synthetases, and ATP sulfurylases [3]. The USPA superfamily contains USPA, ETFP and Photolyases [1]

The clan contains the following 31 members:

Arginosuc_synth Asn_synthase ATP-sulfurylase ATP_bind_3 BshC CDPS Citrate_ly_lig CTP_transf_like Diphthami_syn_2 DNA_photolyase DPRP ETF FAD_syn HIGH_NTase1 HIGH_NTase1_ass NAD_synthase Pantoate_ligase PAPS_reduct QueC ThiI tRNA-synt_1 tRNA-synt_1_2 tRNA-synt_1b tRNA-synt_1c tRNA-synt_1d tRNA-synt_1e tRNA-synt_1f tRNA-synt_1g tRNA_Me_trans UDPG_MGDP_dh_C Usp


We store a range of different sequence alignments for families. As well as the seed alignment from which the family is built, we provide the full alignment, generated by searching the sequence database (reference proteomes) using the family HMM. We also generate alignments using four representative proteomes (RP) sets and the UniProtKB sequence database. More...

View options

We make a range of alignments for each Pfam-A family. You can see a description of each above. You can view these alignments in various ways but please note that some types of alignment are never generated while others may not be available for all families, most commonly because the alignments are too large to handle.

Representative proteomes UniProt
Jalview View  View  View  View  View  View  View 
HTML View             
PP/heatmap 1            

1Cannot generate PP/Heatmap alignments for seeds; no PP data available

Key: ✓ available, x not generated, not available.

Format an alignment

Representative proteomes UniProt

Download options

We make all of our alignments available in Stockholm format. You can download them here as raw, plain text files or as gzip-compressed files.

Representative proteomes UniProt
Raw Stockholm Download   Download   Download   Download   Download   Download   Download  
Gzipped Download   Download   Download   Download   Download   Download   Download  

You can also download a FASTA format file containing the full-length sequences for all sequences in the full alignment.

HMM logo

HMM logos is one way of visualising profile HMMs. Logos provide a quick overview of the properties of an HMM in a graphical form. You can see a more detailed description of HMM logos and find out how you can interpret them here. More...


This page displays the phylogenetic tree for this family's seed alignment. We use FastTree to calculate neighbour join trees with a local bootstrap based on 100 resamples (shown next to the tree nodes). FastTree calculates approximately-maximum-likelihood phylogenetic trees from our seed alignment.

Note: You can also download the data file for the tree.

Curation and family details

This section shows the detailed information about the Pfam family. You can see the definitions of many of the terms in this section in the glossary and a fuller explanation of the scoring system that we use in the scores section of the help pages.

Curation View help on the curation process

Seed source: Pfam-B_888 (release 2.1)
Previous IDs: none
Type: Family
Sequence Ontology: SO:0100021
Author: Bateman A
Number in seed: 11
Number in full: 9465
Average length of the domain: 368.80 aa
Average identity of full alignment: 40 %
Average coverage of the sequence by the domain: 92.17 %

HMM information View help on HMM parameters

HMM build commands:
build method: hmmbuild -o /dev/null HMM SEED
search method: hmmsearch -Z 57096847 -E 1000 --cpu 4 HMM pfamseq
Model details:
Parameter Sequence Domain
Gathering cut-off 21.0 21.0
Trusted cut-off 21.0 21.0
Noise cut-off 20.9 20.9
Model length: 388
Family (HMM) version: 21
Download: download the raw HMM for this family

Species distribution

Sunburst controls


Weight segments by...

Change the size of the sunburst


Colour assignments

Archea Archea Eukaryota Eukaryota
Bacteria Bacteria Other sequences Other sequences
Viruses Viruses Unclassified Unclassified
Viroids Viroids Unclassified sequence Unclassified sequence


Align selected sequences to HMM

Generate a FASTA-format file

Clear selection

This visualisation provides a simple graphical representation of the distribution of this family across species. You can find the original interactive tree in the adjacent tab. More...

Loading sunburst data...

Tree controls


The tree shows the occurrence of this domain across different species. More...


Please note: for large trees this can take some time. While the tree is loading, you can safely switch away from this tab but if you browse away from the family page entirely, the tree will not be loaded.


For those sequences which have a structure in the Protein DataBank, we use the mapping between UniProt, PDB and Pfam coordinate systems from the PDBe group, to allow us to map Pfam domains onto UniProt sequences and three-dimensional protein structures. The table below shows the structures on which the Arginosuc_synth domain has been found. There are 53 instances of this domain found in the PDB. Note that there may be multiple copies of the domain in a single PDB structure, since many structures contain multiple copies of the same protein sequence.

Loading structure mapping...